Cargando…

Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure

The phase 4 observational cohort study assessed the effectiveness and safety of the thrombopoietin receptor agonist avatrombopag in patients with chronic liver disease (CLD) and thrombocytopenia undergoing a procedure. Patients with CLD may have thrombocytopenia, increasing the risk of periprocedura...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satapathy, Sanjaya K., Sundaram, Vinay, Shiffman, Mitchell L., Jamieson, Brian D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553023/ https://www.ncbi.nlm.nih.gov/pubmed/37800793 http://dx.doi.org/10.1097/MD.0000000000035208

Ejemplares similares

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis
por: Lu, Jun, et al.
Publicado: (2022)

Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges
por: Huang, Ao, et al.
Publicado: (2022)

Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
por: Mladsi, Deirdre, et al.
Publicado: (2020)

Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study
por: Wang, Yong-Shuai, et al.
Publicado: (2022)

Correction to: Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
por: Chang, Christine Y., et al.
Publicado: (2017)

A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series
por: Biolato, Marco, et al.
Publicado: (2022)

Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
por: Abdelsamia, Mahmoud, et al.
Publicado: (2023)

Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study
por: Oladapo, Abiola, et al.
Publicado: (2023)

Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia
por: Biolato, Marco, et al.
Publicado: (2022)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Evaluation of the in situ assay for HBV DNA: An observational real-world study in chronic hepatitis B
por: Li, Chang, et al.
Publicado: (2021)

Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation
por: Zhou, Meng, et al.
Publicado: (2022)

Correction to: Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia
Publicado: (2022)

Increased risk of hepatocellular carcinoma in patients with traumatic liver injury: Real-world data from a nationwide population-based study
por: Chen, Yen-Ju, et al.
Publicado: (2022)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents
por: Chen, Yen-Chun, et al.
Publicado: (2020)

Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China
por: Mei, Heng, et al.
Publicado: (2023)

Tension-free hiatal hernia repair with biological mesh: A real-world experience
por: Cheng, Fahui, et al.
Publicado: (2022)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study
por: Li, Juan, et al.
Publicado: (2020)

Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
por: Lee, I-Cheng, et al.
Publicado: (2015)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis
por: Wojciechowski, Piotr, et al.
Publicado: (2021)

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
por: Aiello, Andrea, et al.
Publicado: (2023)

Entecavir-Associated Thrombocytopenia in a Decompensated Cirrhotic Patient: A Case Report and Literature Review
por: Fan, Xiaoli, et al.
Publicado: (2016)

Pre and post-liver transplant outcome of cirrhotic patients with acute on chronic liver failure
por: Iacob, Speranta, et al.
Publicado: (2020)

Liver cirrhosis caused by chronic Budd–Chiari syndrome
por: Lin, Mengjie, et al.
Publicado: (2017)

Case report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease
por: Wu, Tong, et al.
Publicado: (2021)

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies
por: Poordad, Fred, et al.
Publicado: (2020)

A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation
por: Nishikawa, Hiroki, et al.
Publicado: (2016)

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database
por: Tsai, Pei-Chien, et al.
Publicado: (2017)

Serum zinc concentration and quality of life in chronic liver diseases
por: Nishikawa, Hiroki, et al.
Publicado: (2020)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
por: Kolodny, Scott, et al.
Publicado: (2023)

Successful management of thrombocytopenia by partial splenic embolization in patients with advanced gastric cancer and invasion of the splenic vein: Case reports
por: Nakatsubo, Ryosuke, et al.
Publicado: (2021)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jusmd59t0fu331k11hnhv2h20u